The Food and Drug administration announced Friday that it had approved Praluent (alirocumab), a cholesterol-lowering PCSK9 inhibitor injection.
CVS Health weighs in on the next chapter in the debate about the impact of expensive drugs on the healthcare system in a commentary that appears today on the Health Affairs blog.
The Food and Drug Administration has approved a new drug for treating a rare cholesterol disorder, the agency said.
A drug under investigation as a treatment for a rare genetic disorder that causes abnormally high triglyceride levels in the blood has received orphan-drug designation from the Food and Drug Administration.
A drug for treating a genetic cholesterol disorder decreased levels of “bad” LDL cholesterol in...